Skip to main content
Free research Free research Free assay review with research home and workspace preview
Quick search ChEMBL 36
Assay Detail

CHEMBL5503037

Review assay metadata, readout intent, target linkage, and publication context from the same page.

Functional
Inhibition of OVA332 to 339 specific T-cells (unknown origin) proliferation assessed as reduction in B-cell mediated antigen presentation to T cells
1
Total Activities
1
Compounds Tested
1
Activity Types
0
Assay Parameters

Assay Information

Assay Type Functional
Organism Not specified
Cell Type T-cell
Confidence 0 — Uncurated / Unknown
Curated By Autocuration

Target

Unchecked (CHEMBL612545)
Type UNCHECKED

Publication

Discovery and Preclinical Characterization of BIIB129, a Covalent, Selective, and Brain-Penetrant BTK Inhibitor for the Treatment of Multiple Sclerosis.
Himmelbauer MK, Bajrami B, Basile R, Capacci A, Chen T, Choi CK, Gilfillan R, Gonzalez-Lopez de Turiso F, Gu C, Hoemberger M, Johnson DS, Jones JH, Kadakia E, Kirkland M, Lin EY, Liu Y, Ma B, Magee T, Mantena S, Marx IE, Metrick CM, Mingueneau M, Murugan P, Muste CA, Nadella P, Nevalainen M, Parker Harp CR, Pattaropong V, Pietrasiewicz A, Prince RJ, Purgett TJ, Santoro JC, Schulz J, Sciabola S, Tang H, Vandeveer HG, Wang T, Yousaf Z, Helal CJ, Hopkins BT.
J Med Chem (2024) 67 : 8122 -8140
PubMed 38712838 · DOI

Activity Statistics

Type Count Avg pChEMBL Best pChEMBL
IC50 1 8.72 8.72

Compounds Tested

Compound Name Phase Activities Best pChEMBL
CHEMBL5532458 1 8.72

Activity Data

Compound Name Type Rel. Value Units pChEMBL
CHEMBL5532458 IC50 = 1.9 nM 8.72